Priovant Therapeutics announced positive results from its Phase II BEACON study evaluating brepocitinib, a dual selective inhibitor of TYK2 and JAK1, in patients with cutaneous sarcoidosis (CS). Brepocitinib represents the first drug to produce a positive readout in a placebo-controlled study for CS, with Priovant planning to consult with the US FDA before advancing to Phase III study.
The BEACON study enrolled 31 patients across 15 US sites, randomizing participants to receive brepocitinib at 45mg, 15mg, or placebo. The 45mg arm comprised the most treatment-refractory group, with patients presenting longstanding disease and challenging plaque-predominant morphology.
Key efficacy endpoints all demonstrated improvements. The 45mg dose achieved a 22.3-point mean improvement in the Cutaneous Sarcoidosis Activity and Morphology Instrument – Activity score (CSAMI-A), compared to a 0.7-point improvement in the placebo group (P<0.0001). Notably, 100% of patients in the 45mg arm achieved at least a 10-point improvement, with 69% reaching the gold standard two-point improvement on the Investigator's Global Assessment.
Safety data appeared promising, with no serious adverse events and all reported events classified as mild or moderate. This profile suggests potential for broader clinical application in cutaneous sarcoidosis treatment.
Research context
Cutaneous sarcoidosis occurs in 20-35% of systemic sarcoidosis patients, presenting with diverse, often red-brown or purple, skin lesions such as papules, nodules, plaques, or lupus pernio. Frequently affecting the face, neck, and old scars, it is caused by granulomatous inflammation. Therapeutic development is limited by rarity and heterogeneity, with no FDA-approved therapies specifically for CS. Practice still relies on topical/intralesional corticosteroids for localized disease and systemic immunomodulators (hydroxychloroquine, methotrexate, tetracyclines) for more severe disease.
The JAK-STAT pathway is now understood to be central to the formation and maintenance of the granulomas (clumps of inflammatory cells) that characterize sarcoidosis. Brepocitinib’s unique mechanism targets multiple inflammatory pathways by selectively inhibiting TYK2 and JAK1. This approach suppresses key cytokines including type I and II interferons, IL-6, IL-12, and IL-23 – critical mediators in granulomatous inflammatory conditions like sarcoidosis.
Several academic institutions have carried out clinical trials for JAK inhibitors such as tofacitinib in CS, showing improvement in CSAMI activity score and accompanying molecular pathway suppression consistent with reduced type 1 immune signaling. Other novel competitors under development include:
- Bristol Myers Squibb’s deucravacitinib, a selective TYK2 inhibitor in Phase II/III development
- Pfizer’s ritlecitinib, a JAK3 inhibitor exploring inflammatory conditions
Priovant plans to initiate a Phase III program for brepocitinib in CS during calendar year 2026, following engagement with the US FDA. This represents the third indication for brepocitinib’s development, alongside ongoing programs in dermatomyositis and non-infectious uveitis.